Literature DB >> 16140764

An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.

Shigeru Morikawa1, Tokuki Sakiyama, Hideki Hasegawa, Masayuki Saijo, Akihiko Maeda, Ichiro Kurane, Go Maeno, Junko Kimura, Chie Hirama, Teruhiko Yoshida, Yasuko Asahi-Ozaki, Tetsutaro Sata, Takeshi Kurata, Asato Kojima.   

Abstract

The potential threat of smallpox bioterrorism has made urgent the development of lower-virulence vaccinia virus vaccines. An attenuated LC16m8 (m8) vaccine was developed in 1975 from the Lister strain used in the World Health Organization smallpox eradication program but was not used against endemic smallpox. Today, no vaccines can be tested with variola virus for efficacy in humans, and the mechanisms of immune protection against the major intracellular mature virion (IMV) and minor extracellular enveloped virion (EEV) populations of poxviruses are poorly understood. Here, we determined the full-genome sequences of the m8, parental LC16mO (mO), and grandparental Lister (LO) strains and analyzed their evolutionary relationships. Sequence data and PCR analysis indicated that m8 was a progeny of LO and that m8 preserved almost all of the open reading frames of vaccinia virus except for the disrupted EEV envelope gene B5R. In accordance with this genomic background, m8 induced 100% protection against a highly pathogenic vaccinia WR virus in mice by a single vaccination, despite the lack of anti-B5R and anti-EEV antibodies. The immunogenicity and priming efficacy with the m8 vaccine consisting mainly of IMV were as high as those with the intact-EEV parental mO and grandparental LO vaccines. Thus, mice vaccinated with 10(7) PFU of m8 produced low levels of anti-B5R antibodies after WR challenge, probably because of quick clearance of B5R-expressing WR EEV by strong immunity induced by the vaccination. These results suggest that priming with m8 IMV provides efficient protection despite undetectable levels of immunity against EEV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140764      PMCID: PMC1212643          DOI: 10.1128/JVI.79.18.11873-11891.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Smallpox vaccine development quickened.

Authors:  K Birmingham; G Kenyon
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

2.  Transmission potential of smallpox in contemporary populations.

Authors:  R Gani; S Leach
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

3.  The purification fo four strains of poxvirus.

Authors:  W K JOKLIK
Journal:  Virology       Date:  1962-09       Impact factor: 3.616

Review 4.  The looming threat of bioterrorism.

Authors:  D A Henderson
Journal:  Science       Date:  1999-02-26       Impact factor: 47.728

5.  Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.

Authors:  M C Galmiche; J Goenaga; R Wittek; L Rindisbacher
Journal:  Virology       Date:  1999-02-01       Impact factor: 3.616

6.  Base-calling of automated sequencer traces using phred. I. Accuracy assessment.

Authors:  B Ewing; L Hillier; M C Wendl; P Green
Journal:  Genome Res       Date:  1998-03       Impact factor: 9.043

7.  Base-calling of automated sequencer traces using phred. II. Error probabilities.

Authors:  B Ewing; P Green
Journal:  Genome Res       Date:  1998-03       Impact factor: 9.043

8.  Extracellular enveloped vaccinia virus escapes neutralization.

Authors:  Y Ichihashi
Journal:  Virology       Date:  1996-03-15       Impact factor: 3.616

9.  Modeling potential responses to smallpox as a bioterrorist weapon.

Authors:  M I Meltzer; I Damon; J W LeDuc; J D Millar
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

10.  Developing new smallpox vaccines.

Authors:  S R Rosenthal; M Merchlinsky; C Kleppinger; K L Goldenthal
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more
  34 in total

1.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

2.  Genome of horsepox virus.

Authors:  E R Tulman; G Delhon; C L Afonso; Z Lu; L Zsak; N T Sandybaev; U Z Kerembekova; V L Zaitsev; G F Kutish; D L Rock
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

4.  Orthopox Viruses: Infections in Humans.

Authors:  Georg Pauli; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

Review 5.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

6.  The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.

Authors:  Jonathan S Duke-Cohan; Kristin Wollenick; Elizabeth A Witten; Michael S Seaman; Lindsey R Baden; Raphael Dolin; Ellis L Reinherz
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

7.  Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Authors:  Clement A Meseda; Anne E Mayer; Arunima Kumar; Alonzo D Garcia; Joseph Campbell; Paul Listrani; Jody Manischewitz; Lisa R King; Hana Golding; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

8.  Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Authors:  Douglas W Grosenbach; Robert Jordan; David S King; Aklile Berhanu; Travis K Warren; Dana L Kirkwood-Watts; Shanthakumar Tyavanagimatt; Ying Tan; Rebecca L Wilson; Kevin F Jones; Dennis E Hruby
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 4.169

9.  Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice.

Authors:  Hiroyuki Yokote; Yasuhiko Shinmura; Tomomi Kanehara; Shinichi Maruno; Masahiko Kuranaga; Hajime Matsui; So Hashizume
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

10.  Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.

Authors:  Clement A Meseda; Jordan Kuhn; Vajini Atukorale; Joseph Campbell; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.